Chatbots Need Guardrails to Prevent Delusions and Psychosis

The framing around 'guardrails' obscures a harder problem: there is no clinical licensing body, no equivalent to the FDA's 510(k) pathway, and no mandatory incident reporting system that currently applies to companionship AI. The industry is being asked to self-regulate a product category that has already produced documented fatalities.

Anthropic's own internal research on sycophancy, covered here from Simon Willison's May 3rd writeup, found that Claude defers problematically in relationship and spirituality conversations at rates that would concern any clinician. That finding now looks less like an alignment curiosity and more like a documented precondition for the exact harms IEEE Spectrum is flagging. Separately, the RAG medical chatbot security audit from arXiv (May 1st) showed that even well-resourced teams deploying AI in regulated health contexts are shipping without adequate safeguards, suggesting the governance gap is structural rather than specific to any one vendor. The Harvard diagnostic accuracy study and DeepMind's co-clinician work show the industry moving aggressively into clinical adjacency, which makes the absence of harm-prevention standards more consequential, not less.

Watch whether Character.AI or any companionship platform announces a formal clinical advisory board or third-party safety audit before the end of Q3 2026. If none do, that signals the industry is betting on regulatory lag rather than voluntary remediation.